Literature DB >> 21931018

Is the easier way ever the better way?

Dennis S Chi1, Robert E Bristow, Deborah K Armstrong, Beth Y Karlan.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21931018     DOI： 10.1200/JCO.2011.35.9935

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  23 in total

1.  Risk stratification and outcomes of women undergoing surgery for ovarian cancer.

Authors:  Sonali Patankar; William M Burke; June Y Hou; Ana I Tergas; Yongmei Huang; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2015-05-11       Impact factor: 5.482

2.  The optimal time for surgery in women with serous ovarian cancer.

Authors:  Jocelyn M Stewart; Alicia A Tone; Haiyan Jiang; Marcus Q Bernardini; Sarah Ferguson; Stephane Laframboise; K Joan Murphy; Barry Rosen; Taymaa May
Journal:  Can J Surg       Date:  2016-08       Impact factor: 2.089

3.  Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer.

Authors:  Maria Lee; Hyunjong Lee; Gi Jeong Cheon; Hee Seung Kim; Hyun Hoon Chung; Jae-Weon Kim; Noh-Hyun Park; Yong Sang Song
Journal:  Eur Radiol       Date:  2016-04-27       Impact factor: 5.315

4.  Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.

Authors:  Jason D Wright; Cande V Ananth; Jennifer Tsui; Sherry A Glied; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman
Journal:  Cancer       Date:  2014-01-17       Impact factor: 6.860

5.  Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.

Authors:  Ashley L Cole; Emma L Barber; Anagha Gogate; Arthur-Quan Tran; Stephanie B Wheeler
Journal:  Int J Gynecol Cancer       Date:  2018-07       Impact factor: 3.437

6.  Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer.

Authors:  Hyun Hoon Chung; Jae-Weon Kim; Noh-Hyun Park; Yong Sang Song; Gi Jeong Cheon
Journal:  Eur Radiol       Date:  2017-12-19       Impact factor: 5.315

Review 7.  Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States.

Authors:  Ashley L Cole; Anna E Austin; Ryan P Hickson; Matthew S Dixon; Emma L Barber
Journal:  Cancer Epidemiol       Date:  2018-05-25       Impact factor: 2.984

8.  Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.

Authors:  Jennifer J Mueller; Qin C Zhou; Alexia Iasonos; Roisin E O'Cearbhaill; Farah A Alvi; Amr El Haraki; Ane Gerda Zahl Eriksson; Ginger J Gardner; Yukio Sonoda; Douglas A Levine; Carol Aghajanian; Dennis S Chi; Nadeem R Abu-Rustum; Oliver Zivanovic
Journal:  Gynecol Oncol       Date:  2016-01-09       Impact factor: 5.482

9.  The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Authors:  Mani Nassir; Jun Guan; Hrvoje Luketina; Timo Siepmann; Irena Rohr; Rolf Richter; Dan Cacsire Castillo-Tong; Robert Zeillinger; Ignace Vergote; Els Van Nieuwenhuysen; Nicole Concin; Christian Marth; Christina Hall; Sven Mahner; Linn Woelber; Jalid Sehouli; Elena Ioana Braicu
Journal:  Tumour Biol       Date:  2015-09-29

Review 10.  Clinical trials of neoadjuvant chemotherapy for ovarian cancer: what do we gain after an EORTC trial and after two additional ongoing trials are completed?

Authors:  Keiichi Fujiwara; Akira Kurosaki; Kosei Hasegawa
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.